References
- Engström A. Fighting an old disease with modern tools: characteristics and molecular detection methods of drug-resistant Mycobacterium tuberculosis. Infect Dis (London). 2016;48:1–17.
- Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández Turégano C, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line anti tuberculous drugs. Antimicrobial Agents Chemotherapy. 2003;47:416–417.
- Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2010;50:49–55.
- Kjöllerström P, Brito MJ, Gouveia C, et al. Linezolid in the treatment of multidrug resistant/extensively drug-resistant tuberculosis in paediatric patients: experience of a paediatric infectious diseases unit. Scand J Infect Dis. 2011;43:556–559.
- Rose PC, Hallbauer UM, Seddon JA, et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis. 2012;16:1588–1593.
- Pinon M, Scolfaro C, Bignamini E, et al. Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin. Pediatrics. 2010;126:e1253–e1256.
- World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis–2006 [citied 2011 Dec 31]. Available from: http://www.tbrieder.org/publications/books_english/who_treatment_mdr.pdf.
- Agarwal DK, Agarwal KN, Upadhyay SK, et al. Physical and sexual growth pattern of affluent Indian children from 5 to 18 years of age. Indian Pediatr. 1992;29:1203–1282.
- Pharmacia and Upjohn Company. Zyvox: linezolid injection, linezolid tablets, linezolid for oral suspension package insert. Kalamazoo, MI: Pharmacia and Upjohn Company; 2002.
- Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004; 4:528–531.